“…Fructose‐1,6‐bisphosphate (F1,6 BP ), an endogenous intermediate of the glycolytic pathway, is produced through phosphorylation of fructose 6‐phosphate by the phosphofructokinase‐1 activity (Kirtley & McKay, 1977). Its therapeutic effects have been documented in a wide range of pathological situations, including sepsis (Catarina et al, 2018), hepatic diseases (De Mesquita et al, 2013), and nephrotoxicity (Azambuja et al, 2011). Also, it was demonstrated that F1,6 BP has antiproliferative effects against hepatocellular carcinoma (Lima et al, 2018; Lu, Yu, & Zhu, 2014) and papillary carcinoma (Li, Wei, Shen, & Hu, 2014).…”